2023-08-09 06:19:37 ET
Benitec Biopharma ( NASDAQ: BNTC ) priced its underwritten public offering of ~15.54M shares and warrants to purchase up to ~15.54M shares.
The offering is expected to close on August 11, 2023.
Underwriters have a 30 day option to purchase an additional ~2.33M shares.
The aggregate gross proceeds are expected to be ~$30M.
Net proceeds from this financing to support the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities.
The stock price is down 1% before Wednesday market open.
For further details see:
Benitec Biopharma prices $30M equity offering